. 2021 May 4;325(20):2067–2075. doi: 10.1001/jama.2021.6118

Table 2. Improvement by Medication Type in a Study of α₂-Adrenergic Agonists vs Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.

Level of improvement^a	No. (%) [95% CI]		Difference (95% CI)
Level of improvement^a	α₂-Adrenergic agonist (n = 175)	Stimulants (n = 321)^b	Difference (95% CI)
Very much improved	43 (25) [16 to 33]	121 (38) [30 to 46]	−13 (−25 to −1)
Much improved	72 (41) [32 to 50]	129 (40) [33 to 47]	1 (−10 to 12)
No improvement	60 (34) [26 to 42]	71 (22) [17 to 28]	12 (2 to 22)

^{^a}

Level of improvement was inferred by the data abstractor applying the clinical global improvement scale portions that were able to be abstracted from medical records, with minimally improved being collapsed with no change and worse, and separate categories for much improved and very much improved.

^{^b}

One child who was treated with stimulant medication (specifically methylphenidate) did not have the clinician identification number available and thus was excluded from these results because the 95% CIs provided were adjusted for clustering by clinician.

Table 2. Improvement by Medication Type in a Study of α2-Adrenergic Agonists vs Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.

Table 2. Improvement by Medication Type in a Study of α₂-Adrenergic Agonists vs Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.